Global Osteoporosis Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2017 to 2025

  • ID: 4431604
  • Report
  • Region: Global
  • Acute Market Reports
1 of 4

FEATURED COMPANIES

  • Actavis Plc.
  • Allergan Plc
  • Amgen, Inc.
  • Eli Lilly and Company
  • F. Hoffmann La Roche Ltd.
  • Merck & Co AG
  • MORE
Osteoporosis Treatment Market - Growth, Future Prospects, and Competitive Analysis, 2017 - 2025, the global osteoporosis treatment market was valued at US$ 11,734.8 Mn in 2016, and is expected to reach US$ 16,512.7 Mn by 2025, expanding at a CAGR of 3.9% from 2017 to 2025

Market Insights

Osteoporosis is a bone disease causing loss of bone density that occurs with age. It leads to million broken bones each year, and thus major reason of fractures, spinal problems, back pain, and loss of independence. According to the International Osteoporosis Foundation, around 200 million people suffer from this disease. Around 30% of all postmenopausal women suffer from osteoporosis in U.S. and Europe. It is observed that osteoporosis is one of the most neglected diseases despite the grave consequence it can cause to female health. Thus rising prevalence of osteoporosis is a serious public health concern. Programs to increase awareness of osteoporosis are conducted out by international and national bodies. Thus ageing population, rise in prevalence of osteoporosis, awareness programs are the key factors driving the osteoporosis treatment market.

The global osteoporosis treatment market is segmented by drug type into bisphosphonates, parathyroid hormone therapy, calcitonin, selective estrogen inhibitors modulator (SERM) and rank ligand inhibitors. Bisphosphonates is extensively used for prevention and treatment of osteoporosis, thus dominating the osteoporosis treatment market.

As of the current market scenario, North America dominated the global osteoporosis treatment market followed by the Europe. Around 75 million people are affected by osteoporosis in Europe, U.S. and Japan. Increasing prevalence of osteoporosis and aging population, and growing awareness about osteoporosis are the key factor driving the growth of osteoporosis treatment market. Asia Pacific is the fastest growing regional market for osteoporosis treatment. In emerging economies such as China, India there is rising awareness about prevalence of osteoporosis and enhancement in healthcare infrastructure, improving diagnostic and treatment that would boost the demand of osteoporosis treatment market.

Market Competition Assessment

Key players in the global osteoporosis treatment market are Allergan Plc., Amgen, Inc., Actavis Plc., Eli Lilly and Company, F.Hoffmann La Roche Ltd, GlaxoSmithKline Pharmaceutical Ltd, Merck & Co AG, Novartis AG, Novo Nordisk A/S, Pfizer, Inc., Teva Pharmaceuticals Industries Ltd. and others.

Key Market Movements:
  • Ageing of populations worldwide is major reason for rise in the incidence of osteoporosis. Osteoporosis affects an estimated 75 million people in Europe, U.S. and Japan.
  • Osteoporosis is a grave problem for all postmenopausal women health affecting almost 30% of postmenopausal women in U.S. and Europe.
  • Worldwide, osteoporosis causes more than 8.9 million fractures annually, resulting in an osteoporotic fracture every 3 seconds.
  • Entry of generics especially in emerging economies creates a lucrative opportunity for osteoporosis treatment market. Tymlos is approved by the U.S. FDA to treat osteoporosis in postmenopausal women at high risk of fracture, that would further propel the demand for osteoporosis treatments.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Actavis Plc.
  • Allergan Plc
  • Amgen, Inc.
  • Eli Lilly and Company
  • F. Hoffmann La Roche Ltd.
  • Merck & Co AG
  • MORE
Chapter 1. Preface
1.1. Report Scope and Description
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase II-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted

Chapter 2. Executive Summary
2.1. Global Osteoporosis Treatment Market Portraiture
2.1.1. Global Osteoporosis Treatment Market, by Drug Type, 2016
2.1.2. Global Osteoporosis Treatment Market, by Geography, 2016

Chapter 3. Osteoporosis Treatment: Market Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.4.1. Attractive Investment Proposition, by Geography
3.5. Competitive Landscape
3.5.1. Competitive Landscape, by Key Players, 2016

Chapter 4. Global Osteoporosis Treatment Market, by Drug Type, 2015 - 2025 (US$ Mn)
4.1. Overview
4.2. Attractive Investment Proposition: Global Osteoporosis Treatment Market, by Drug Type
4.3. Bisphosphonates
4.4. Parathyroid Hormone Therapy
4.5. Calcitonin
4.6. Selective Estrogen Inhibitors Modulator (SERM)
4.7. Rank Ligand Inhibitors

Chapter 5. Global Osteoporosis Treatment Market, by Geography, 2015 - 2025 (US$ Mn)
5.1. Overview
5.2. North America Osteoporosis Treatment Market Analysis, 2015 - 2025
5.2.1. North America Osteoporosis Treatment Market, by Drug Type, 2015 - 2025 (US$ Mn)
5.2.2. North America Osteoporosis Treatment Market, by Country, 2015 - 2025 (US$ Mn)
5.2.2.1. U.S.
5.2.2.2. Canada
5.3. Europe Osteoporosis Treatment Market Analysis, 2015 - 2025
5.3.1. Europe Osteoporosis Treatment Market, by Drug Type, 2015 - 2025 (US$ Mn)
5.3.2. Europe Osteoporosis Treatment Market, by Country, 2015 - 2025 (US$ Mn)
5.3.2.1. U.K.
5.3.2.2. Germany
5.3.2.3. France
5.3.2.4. Rest of Europe
5.4. Asia Pacific Osteoporosis Treatment Market Analysis, 2015 - 2025
5.4.1. Asia Pacific Osteoporosis Treatment Market, by Drug Type, 2015 - 2025 (US$ Mn)
5.4.2. Asia Pacific Osteoporosis Treatment Market, by Country, 2015 - 2025 (US$ Mn)
5.4.2.1. Japan
5.4.2.2. China
5.4.2.3. India
5.4.2.4. Rest of APAC
5.5. Latin America Osteoporosis Treatment Market Analysis, 2015 - 2025
5.5.1. Latin America Osteoporosis Treatment Market, by Drug Type, 2015 - 2025 (US$ Mn)
5.5.2. Latin America Osteoporosis Treatment Market, by Country, 2015 - 2025 (US$ Mn)
5.5.2.1. Brazil
5.5.2.2. Mexico
5.5.2.3. Rest of Latin America
5.6. Middle East & Africa (MEA) Osteoporosis Treatment Market Analysis, 2015 - 2025
5.6.1. MEA Osteoporosis Treatment Market, by Drug Type, 2015 - 2025 (US$ Mn)
5.6.2. MEA Osteoporosis Treatment Market, by Country, 2015 - 2025 (US$ Mn)
5.6.2.1. UAE
5.6.2.2. Saudi Arabia
5.6.2.3. South Africa
5.6.2.4. Rest of MEA

Chapter 6. Company Profiles
6.1. Allergan Plc
6.1.1. Business Description
6.1.2. Financial Information (Subject to data availability)
6.1.3. Drug Portfolio
6.1.4. Key Developments
6.2. Amgen, Inc.
6.3. Actavis Plc.
6.4. Eli Lilly and Company
6.5. F. Hoffmann La Roche Ltd.
6.6. GlaxoSmithKline Pharmaceutical Ltd.
6.7. Merck & Co AG
6.8. Novartis AG
6.9. Novo Nordisk A/S
6.10. Pfizer, Inc.
6.11. Teva Pharmaceuticals Industries Ltd.
6.12. Other Notable Players

List of Figures
Fig. 1 Osteoporosis Treatment: Market Segmentation
Fig. 2 Global Osteoporosis Treatment Market Share, by Drug Type, 2016 (US$ Mn)
Fig. 3 Global Osteoporosis Treatment Market, by Geography, 2016 (Value %)
Fig. 4 Attractive Investment Proposition, by Geography
Fig. 5 Market Competition Landscape, by Key Players, 2016
Fig. 6 Global Bisphosphonates Osteoporosis Treatment Market, 2015 - 2025 (US$ Mn)
Fig. 7 Global Parathyroid Hormone Therapy Osteoporosis Treatment Market, 2015 - 2025 (US$ Mn)
Fig. 8 Global Calcitonin Osteoporosis Treatment Market, 2015 - 2025 (US$ Mn)
Fig. 9 Global Selective Estrogen Inhibitors Modulator (SERM) Osteoporosis Treatment Market, 2015 - 2025 (US$ Mn)
Fig. 10 Global Rank Ligand Inhibitors Osteoporosis Treatment Market, 2015 - 2025 (US$ Mn)
Fig. 11 U.S. Osteoporosis Treatment Market, 2015 - 2025 (US$ Mn)
Fig. 12 Canada Osteoporosis Treatment Market, 2015 - 2025 (US$ Mn)
Fig. 13 U.K. Osteoporosis Treatment Market, 2015 - 2025 (US$ Mn)
Fig. 14 Germany Osteoporosis Treatment Market, 2015 - 2025 (US$ Mn)
Fig. 15 France Osteoporosis Treatment Market, 2015-2025 (US$ Mn)
Fig. 16 Rest of Europe Osteoporosis Treatment Market, 2015 - 2025 (US$ Mn)
Fig. 17 Japan Osteoporosis Treatment Market, 2015 - 2025 (US$ Mn)
Fig. 18 China Osteoporosis Treatment Market, 2015 - 2025 (US$ Mn)
Fig. 19 India Osteoporosis Treatment Market, 2015 - 2025 (US$ Mn)
Fig. 20 Rest of Asia Pacific Osteoporosis Treatment Market, 2015 - 2025 (US$ Mn)
Fig. 21 Brazil Osteoporosis Treatment Market, 2015 - 2025 (US$ Mn)
Fig. 22 Mexico Osteoporosis Treatment Market, 2015 - 2025 (US$ Mn)
Fig. 23 Rest of Latin America Osteoporosis Treatment Market, 2015 - 2025 (US$ Mn)
Fig. 24 UAE Osteoporosis Treatment Market, 2015 - 2025 (US$ Mn)
Fig. 25 Saudi Arabia Osteoporosis Treatment Market, 2015 - 2025 (US$ Mn)
Fig. 26 South Africa Osteoporosis Treatment Market, 2015 - 2025 (US$ Mn)
Fig. 27 Rest of Middle East and Africa Osteoporosis Treatment Market, 2015 - 2025 (US$ Mn)

List of Tables
Table 1 Global Osteoporosis Treatment Market, by Drug Type, 2015 - 2025 (US$ Mn)
Table 2 North America Osteoporosis Treatment Market, by Drug Type, 2015 - 2025 (US$ Mn)
Table 3 North America Osteoporosis Treatment Market, by Country, 2015 - 2025 (US$ Mn)
Table 4 Europe Osteoporosis Treatment Market, by Drug Type, 2015 - 2025 (US$ Mn)
Table 5 Europe Osteoporosis Treatment Market, by Country, 2015 - 2025 (US$ Mn)
Table 6 Asia Pacific Osteoporosis Treatment Market, by Drug Type, 2015 - 2025(US$ Mn)
Table 7 Asia Pacific Osteoporosis Treatment Market, by Country, 2015 - 2025(US$ Mn)
Table 8 Latin America Osteoporosis Treatment Market, by Drug Type, 2015 - 2025(US$ Mn)
Table 9 Latin America Osteoporosis Treatment Market, by Country, 2015 - 2025 (US$ Mn)
Table 10 Middle East and Africa Osteoporosis Treatment Market, by Drug Type, 2015 - 2025 (US$ Mn)
Table 11 Middle East and Africa Osteoporosis Treatment Market, by Country, 2015 - 2025 (US$ Mn)
Table 12 Allergan Plc.: Company Snapshot (Business Description, Financial Information, Drug Portfolio, Key Developments)
Table 13 Amgen, Inc.: Company Snapshot (Business Description, Financial Information, Drug Portfolio, Key Developments)
Table 14 Actavis Plc.: Company Snapshot (Business Description, Financial Information, Drug Portfolio, Key Developments)
Table 15 Eli Lilly and Company: Company Snapshot (Business Description, Financial Information, Drug Portfolio, Key Developments)
Table 16 F.Hoffmann La Roche Ltd: Company Snapshot (Business Description, Financial Information, Drug Portfolio, Key Developments)
Table 17 GlaxoSmithKline Pharmaceutical Ltd: Company Snapshot (Business Description, Financial Information, Drug Portfolio, Key Developments)
Table 18 Merck & Co AG: Company Snapshot (Business Description, Financial Information, Drug Portfolio, Key Developments)
Table 19 Novartis AG: Company Snapshot (Business Description, Financial Information, Drug Portfolio, Key Developments)
Table 20 Novo Nordisk A/S: Company Snapshot (Business Description, Financial Information, Drug Portfolio, Key Developments)
Table 21 Pfizer, Inc.: Company Snapshot (Business Description, Financial Information, Drug Portfolio, Key Developments)
Table 22 Teva Pharmaceuticals Industries Ltd.: Company Snapshot (Business Description, Financial Information, Drug Portfolio, Key Developments)
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Allergan Plc
  • Amgen, Inc.
  • Actavis Plc.
  • Eli Lilly and Company
  • F. Hoffmann La Roche Ltd.
  • GlaxoSmithKline Pharmaceutical Ltd.
  • Merck & Co AG
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer, Inc.
  • Teva Pharmaceuticals Industries Ltd.
  • Othe
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll